❌

Reading view

Which Tokens Should SFT Actually Learn? A Token-Trimming Perspective on Mathematical Reasoning

arXiv:2609.09707v1 Announce Type: new Abstract: Supervised fine-tuning (SFT) applies a uniform cross-entropy loss to all target tokens, even though different tokens provide unequal learning signals for mathematical reasoning. This uniform treatment can over-sharpen already mastered tokens while amplifying learning pressure on uncertain, low-confidence tokens, leading to suboptimal training dynamics. We propose Trimmed Logit-Gap SFT (TrimSFT), a simple token-level reweighting method that scales the SFT loss according to the logit gap between the gold token and its strongest competitor. TrimSFT trims supervision away from both extremes: tokens already mastered (large logit gap) and tokens weakly supported by the current model (small or negative logit gap), concentrating learning within an intermediate logit-gap region between them. We instantiate this principle with a Gaussian weight centered at margin m with bandwidth {\tau}, requiring no reference model or additional forward pass. We evaluate TrimSFT on six base models from the Llama, Qwen, and DeepMath families across five mathematical reasoning benchmarks. TrimSFT consistently improves over standard SFT, achieving the best average performance on five out of six models, with gains of up to +26.9 points over SFT on MATH500. Further analyses show that the bandwidth {\tau} matters more than the exact margin location, and that half-trim variants that remove supervision pressure from only one side yield inferior trade-offs. A token-level logit-gap distribution analysis suggests that TrimSFT reshapes model confidence in a more balanced way than uniform SFT or monotonic reweighting methods. These results suggest that reasoning SFT can benefit from trimming both extremes rather than treating all tokens uniformly.
  •  

Early stage nonsmall cell lung cancer: Toward a risk-adaptive paradigm in the era of biologic precision

CA Cancer J Clin. 2026 Sep-Oct;76(5):e70100. doi: 10.3322/caac.70100.

ABSTRACT

The clinical landscape of early stage nonsmall cell lung cancer is at transformative crossroads. Driven by the widespread adoption of low-dose computed tomography screening, the frequent detection of ground-glass opacities, and a rising incidence among never-smokers, the diagnostic center of gravity has shifted toward earlier, potentially curable disease. This shift has been accompanied by equally important therapeutic advances, including parenchyma-sparing surgical techniques, minimally invasive platforms enhanced by digital navigation, and the transformative integration of perioperative immunotherapy and targeted agents. Concurrently, noninvasive monitoring approaches, such as liquid biopsy, have emerged as powerful tools to guide precision management. Despite this progress, substantial barriers to achieving a universal cure persist. Clinicians continue to face uncertainty in the management of ground-glass opacities, the anatomy-based TNM staging system fails to capture the biologic heterogeneity of early tumors, and global disparities in access to innovation remain unresolved. To address these challenges, the authors propose a shift toward a risk-adaptive management paradigm that harnesses artificial intelligence-driven analytics and multi-omics profiling to tailor treatment intensity according to each patient's biologic risk. Such an approach would enable appropriate escalation for high-risk individuals while permitting safe de-escalation for those at low risk. This holistic, lifespan-oriented strategy must be embraced to deliver equitable and durable cures for patients with early stage nonsmall cell lung cancer.

PMID:42713910 | PMC:PMC13555834 | DOI:10.3322/caac.70100

  •  

Early stage nonsmall cell lung cancer: Toward a risk-adaptive paradigm in the era of biologic precision

CA Cancer J Clin. 2026 Sep-Oct;76(5):e70100. doi: 10.3322/caac.70100.

ABSTRACT

The clinical landscape of early stage nonsmall cell lung cancer is at transformative crossroads. Driven by the widespread adoption of low-dose computed tomography screening, the frequent detection of ground-glass opacities, and a rising incidence among never-smokers, the diagnostic center of gravity has shifted toward earlier, potentially curable disease. This shift has been accompanied by equally important therapeutic advances, including parenchyma-sparing surgical techniques, minimally invasive platforms enhanced by digital navigation, and the transformative integration of perioperative immunotherapy and targeted agents. Concurrently, noninvasive monitoring approaches, such as liquid biopsy, have emerged as powerful tools to guide precision management. Despite this progress, substantial barriers to achieving a universal cure persist. Clinicians continue to face uncertainty in the management of ground-glass opacities, the anatomy-based TNM staging system fails to capture the biologic heterogeneity of early tumors, and global disparities in access to innovation remain unresolved. To address these challenges, the authors propose a shift toward a risk-adaptive management paradigm that harnesses artificial intelligence-driven analytics and multi-omics profiling to tailor treatment intensity according to each patient's biologic risk. Such an approach would enable appropriate escalation for high-risk individuals while permitting safe de-escalation for those at low risk. This holistic, lifespan-oriented strategy must be embraced to deliver equitable and durable cures for patients with early stage nonsmall cell lung cancer.

PMID:42713910 | DOI:10.3322/caac.70100

  •  
❌